Despite our best efforts, sometimes errors make it into the final newsletter. We’d like to thank Dr. Jonathan Gamze for pointing out the following errors in Volume 3, Number 5 (Substance Abuse, November 2012): 1) Antabuse was listed as available as a 200 mg pill; in fact it is available in a 250 mg pill; 2) Suboxone is a combination of buprenorphine and naloxone, not buprenorphine and naltrexone, as erroneously stated in the report. Our apologies.
What steps should clinicians take if psychopharmacologic treatments and school behavioral strategies are insufficient for managing a child with ADHD? We've all been there. ADHD,...